Search research articles
Contact Us
Filters
Showing results (81-90 of 133) with videos related to
Page
of 14
Sort By:
Cancer
|
October 19, 2017
Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial
John V Hegde, Narek Shaverdian, Megan E Daly, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Cancer Chemotherapy and Pharmacology
|
July 30, 2022
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
Justin A Chen, Jasmine C Huynh, Chun-Yi Wu, et al.
JTO Clinical and Research Reports
|
September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
Marissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
Cancer Research
|
December 13, 2018
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Dana S Neel, David V Allegakoen, Victor Olivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations
Thereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.
Oncology and Therapy
|
October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
Balazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 133) with videos related to
Sort By:
Page
of 14
Cancer
|
October 19, 2017
Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial
John V Hegde, Narek Shaverdian, Megan E Daly, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Cancer Chemotherapy and Pharmacology
|
July 30, 2022
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
Justin A Chen, Jasmine C Huynh, Chun-Yi Wu, et al.
JTO Clinical and Research Reports
|
September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
Marissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
Cancer Research
|
December 13, 2018
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Dana S Neel, David V Allegakoen, Victor Olivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations
Thereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.
Oncology and Therapy
|
October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
Balazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.
Page
of 14